United States RE46290 (Brain Cancer): What the Claim Set Covers and Where the Landscape Sits

RE46290 is a US reissue that recites a method-of-treatment framework for brain cancer using a pharmaceutical composition containing a compound of “Formula (I)” (or a pharmaceutically acceptable salt), with broad treatment-use conditions and several anchored add-on elements (second therapy classes, specific anti-cancer/anti-angiogenic exemplars, route-of-administration breadth, and a TNF-related apoptosis-inducing ligand measurement element).

Because the claim text you provided does not include the underlying compound definition for “Formula (I),” the analysis below stays at the level of claim scope, functional boundaries, and enforceability hooks that can be inferred from the claim language itself.

What is the enforceable core of RE46290’s method claims?

Claim 1 defines the main method grant

Claim 1:

“A method of treatment of a subject having brain cancer”
comprising administering:
- a pharmaceutical composition with a “pharmaceutically effective amount of a compound of Formula (I)” (or salt), and
- a “pharmaceutically acceptable carrier.”

This is the core that drives most potential infringement scenarios: if a regimen includes administration of the Formula (I) compound (or salt) at a pharmaceutically effective amount as part of treatment of a brain cancer subject, the method is in play.

Claim 2 locks to a specific tumor type

Claim 2: brain cancer is glioblastoma multiforme.
This narrows claim scope for a dependent claim but also identifies a high-value target indication where combination regimens and biomarker-linked assessments are commonly pursued.

Claims 3 and 4 create “second therapeutic” dependent variations

Claim 3: adds a step “further comprising administering a second therapeutic” where the second agent is an “anti-cancer agent.”
Claim 4: adds a step “further comprising administering a second therapeutic” where the second agent is an “anti-angiogenic agent.”

These dependent claims broaden practical coverage of clinical practice, because most brain cancer management involves multi-agent therapy. They also create two separate dependent claim paths based on the class of the “second therapeutic.”

Claims 5 through 7 specify exemplars within the second therapeutic branches

Claim 5: the anti-cancer agent is a “mitotic inhibitor.”
Claim 6: mitotic inhibitor selected from paclitaxel, docetaxel, or combinations.
Claim 7: anti-angiogenic agent is bevacizumab.

These exemplars matter because they reduce ambiguity for infringement analysis for those particular second therapies. They also signal the likely clinical regimen classes the patentee intended to capture.

Claims 8 and 9 expand route-of-administration coverage

Claim 8: composition administered orally.
Claim 9: route may be selected from a long enumerated list including rectal, nasal, pulmonary, epidural, ocular, otic, intraarterial, intracardiac, intracerebroventricular, intradermal, intravenous, intramuscular, intraperitoneal, intraosseous, intrathecal, intravesical, subcutaneous, topical, transdermal, transmucosal, sublingual, buccal, vaginal, inhalational.

This is unusually broad for a method claim. It reduces design-around leverage based on delivery route, provided the regimen still involves administering the Formula (I) compound in a “pharmaceutically effective amount” with a “pharmaceutically acceptable carrier.”

Claims 10 through 12 add a biomarker measurement component

Claim 10: includes “further including assessing effectiveness of the treatment.”
Claim 11: effectiveness assessment comprises assaying TNF-related apoptosis-inducing ligand (TRAIL) in a biological sample.
Claim 12: sample is blood, serum, plasma, or cerebrospinal fluid.

This branch can capture not only treatment dosing but also a clinical workflow in which therapy effectiveness is monitored using TRAIL assay in relevant biological matrices. It also provides a distinct evidentiary handle (the assay) for proving that “assessing effectiveness” was part of the method performed.

How broad is RE46290’s scope across patient population, cancer type, and treatment steps?

Patient population and cancer type

Base indication: “subject having brain cancer.”
Specific dependent indication: glioblastoma multiforme (GBM).

Practical scope consequence: Claim 1 covers multiple brain cancer categories, while Claim 2 focuses on GBM. In enforcement, plaintiffs often assert the broader independent claim first (Claim 1), then add dependent claims to strengthen the match to clinical protocols used in GBM.

Treatment step: “administering” a Formula (I) composition

The claim requires:

administration of a “pharmaceutical composition”
containing a pharmaceutically effective amount of a compound of Formula (I) or salt
plus a pharmaceutically acceptable carrier

This is a standard method-of-treatment structure. The main scoping variables are:

what falls within “Formula (I)” and salts
whether the administered amount is “pharmaceutically effective”
whether the administration is for treating brain cancer (not incidental use)

Regimen complexity: optional second therapeutic step

Claim 3: second anti-cancer therapy is required for that dependent path.
Claim 4: second anti-angiogenic therapy is required for that dependent path.
Claims 5 to 7 specify classes and exemplars within those dependent paths.

This yields two distinct claim overlays for combination treatment:

Combination with a mitotic inhibitor (paclitaxel/docetaxel).
Combination with an anti-angiogenic agent (bevacizumab).

If clinical development uses those exact second-agent classes/exemplars in a GBM regimen including Formula (I), the dependent claims become directly relevant.

What do the combination therapy sub-claims capture that clinicians actually do?

Second therapeutic as “anti-cancer agent” (Claim 3) and “mitotic inhibitor” (Claim 5)

Claim 3 makes the second-agent requirement class-based: any anti-cancer agent qualifies if it is a “second therapeutic agent comprises an anti-cancer agent.”

Claim 5 then narrows to “mitotic inhibitor,” which is a functional mechanism classification. In practice, that can be narrower than the broader anti-cancer universe.

Claim 6 further narrows to:

paclitaxel
docetaxel
combinations

This is significant because paclitaxel/docetaxel are classic mitotic inhibitors. If Formula (I) is combined with these agents in brain cancer treatment, Claim 6 becomes a tight infringement target.

Second therapeutic as “anti-angiogenic agent” (Claim 4) and “bevacizumab” (Claim 7)

Claim 4 captures anti-angiogenic agents at the class level.
Claim 7 narrows to bevacizumab.

This matters because bevacizumab has a documented history of use in high-grade gliomas and is often part of combination regimens. Where the Formula (I) compound is administered alongside bevacizumab as part of treatment of brain cancer (especially GBM), Claim 7 becomes an enforcement-critical dependent claim.

How strong is route-of-administration coverage for infringement-proofing?

Oral and multi-route enumerations (Claims 8-9)

Claim 8: oral administration is explicitly covered.
Claim 9: administration covers an enumerated set that includes common and niche CNS-relevant routes:
- intravenous
- intrathecal
- intracerebroventricular
- epidural
- inhalational, topical/transdermal/mucosal routes, and others

This breadth limits “we don’t inject it” design-around arguments. Many delivery alternatives in CNS oncology are still routed through one of the enumerated delivery modes.

In practice, the route language increases the chance that a single clinical protocol will map to at least one claim route option, even if the formulation/delivery differs.

What does the TRAIL biomarker clause add to the enforcement and design-around calculus?

“Assessing effectiveness” is part of the claimed method

Claims 10 to 12 are not merely correlational; they add a procedural step:

“further including assessing effectiveness”
via “assaying TNF-related apoptosis-inducing ligand (TRAIL)”
in specified samples (blood/serum/plasma/CSF)

This means an accused clinical method would need to include an effectiveness assessment using TRAIL in one of the enumerated matrices as part of performing the claimed method, at least for the dependent claim coverage.

Evidentiary leverage: the assay and the sample types

TRAIL measurement provides:

a measurable lab step
a documentation trail in clinical records and lab reports
a constrained list of sample matrices: blood, serum, plasma, cerebrospinal fluid

For enforcement, the biomarker sub-claims can be used to align the claim to actual clinical practice. For design-around, avoidance would require changing the monitoring strategy or using a different biomarker approach such that the claimed TRAIL assay step is not performed as “assessing effectiveness.”

What is the likely patent landscape posture around RE46290’s claim framework?

Landscape drivers implied by the claim set

Even without the Formula (I) definition, RE46290’s claim architecture implies three landscape clusters that tend to coexist in brain cancer portfolios:

Drug composition claims for the Formula (I) compound or salts
- Method claim depends on the compound’s identity and “pharmaceutically acceptable carrier.”
- Those identities typically trace to earlier composition or chemical patent families.
Combination-therapy coverage
- Dependent claims explicitly name mitotic inhibitors (paclitaxel/docetaxel) and bevacizumab.
- This suggests the patentee expected combination use to be commercially meaningful.
Biomarker-linked clinical workflow claims
- The TRAIL assay element suggests a secondary claim strategy tied to translational medicine and monitoring.
- Many firms hold separate biomarker patents or application-specific monitoring patents.

How reissue tends to affect landscape interpretation

A reissue generally indicates either:

correction of earlier claim scope/wording, or
refinement to improve claim coverage.

In landscape terms, RE46290 often functions as a “scope-corrected” method layer, sitting atop an underlying chemical/composition family and potentially reinforcing combination and biomarker claims.

Where are the clearest “hit zones” for product and clinical protocol infringement risk?

The highest-risk scenarios are where all of the following occur:

The regimen treats brain cancer (GBM strongly implicated).
A product administered contains a compound that falls within “Formula (I)” (or a pharmaceutically acceptable salt).
The regimen matches at least one dependent path:
- Second therapeutic is paclitaxel/docetaxel (mitotic inhibitor) and the protocol follows the “further comprising” step (Claim 6), or
- Second therapeutic is bevacizumab (Claim 7), or
- The monitoring workflow includes assessing effectiveness using a TRAIL assay in blood/serum/plasma/CSF (Claims 10-12).
The administration route matches any of the covered options (Claim 8-9).

Key claim-to-risk matrix

Claim element	What it covers	Practical infringement “hit zone”
Claim 1: method treatment of brain cancer using Formula (I) composition + carrier	Core regimen step	Any protocol in which Formula (I) compound is administered for brain cancer treatment
Claim 2: GBM	Specific indication	GBM clinical protocols are the primary mapping targets
Claim 3-4: add second therapeutic	Combination requirement by class	Multi-agent regimens with an added anti-cancer or anti-angiogenic agent
Claim 5-6: paclitaxel/docetaxel mitotic inhibitor	Specific exemplar	Any regimen combining Formula (I) with paclitaxel/docetaxel
Claim 7: bevacizumab	Specific exemplar	Any regimen combining Formula (I) with bevacizumab
Claim 8-9: routes incl oral, IV, intrathecal, intracerebroventricular, etc.	Delivery-route flexibility	Protocol changes in route still likely fall within enumerated options
Claim 10-12: effectiveness assessment via TRAIL assay	Monitoring workflow	Trials/clinical care where TRAIL is assayed for effectiveness in listed specimen types

Business implications: portfolio strategy and freedom-to-operate filters

For product developers using similar combination regimens

If development plans include paclitaxel or docetaxel as a mitotic inhibitor partner, and include the Formula (I) compound in a brain cancer indication, Claim 6 becomes a near-direct scope check.
If bevacizumab is used as an anti-angiogenic partner with the Formula (I) compound, Claim 7 becomes a direct check.

For clinical development teams designing companion diagnostics / monitoring

Including TRAIL assay in blood/serum/plasma/CSF as part of effectiveness assessment can pull the protocol into Claims 10-12.
Monitoring strategy becomes a legal design variable, not only a clinical choice.

For formulation and delivery programs

Because the route claim is enumerated across many administration methods, route selection is less likely to provide a clean escape. The key gating factor remains whether the administered active is within Formula (I).

Key Takeaways

RE46290’s claim set is built around a method of treating brain cancer by administering a composition containing a “Formula (I)” compound (or salt) with a pharmaceutically acceptable carrier.
Dependent claims anchor the landscape on three enforcement vectors: combination partners (mitotic inhibitors paclitaxel/docetaxel; anti-angiogenic bevacizumab) and a TRAIL-based effectiveness assessment workflow in blood/serum/plasma/CSF.
Route-of-administration is broadly enumerated, leaving limited room for design-around via administration route alone.
The biomarker clause adds a procedural step that can align closely with clinical trial documentation and lab practices, increasing the evidentiary specificity for that dependent claim path.

FAQs

1) Does Claim 1 require combination therapy?

No. Claim 1 alone requires administering the Formula (I) composition for brain cancer treatment. Combination elements appear only in dependent claims (Claims 3-7).

2) Which dependent claims name specific second therapeutic drugs?

Paclitaxel and docetaxel are named in Claims 5-6 (mitotic inhibitor branch). Bevacizumab is named in Claim 7 (anti-angiogenic branch).

3) Is oral administration explicitly covered?

Yes. Claim 8 explicitly includes oral administration.

4) What biomarker is tied to “assessing effectiveness”?

TNF-related apoptosis-inducing ligand (TRAIL), assayed in blood, serum, plasma, or cerebrospinal fluid under Claims 10-12.

5) If the protocol uses a different route of administration not listed, does RE46290 still apply?

Claim 9 enumerates many routes and Claim 8 covers oral. Outside those enumerated routes, the specific dependent route language may not map, but Claim 1 still requires administration of the Formula (I) composition for brain cancer treatment.

References

[No sources cited]

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Chimerix	MODEYSO	dordaviprone hydrochloride	CAPSULE;ORAL	219876-001	Aug 6, 2025		RX	Yes	Yes	RE46290	⤷ Start Trial				METHOD OF TREATING ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH DIFFUSE MIDLINE GLIOMA HARBORING AN H3 K27M MUTATION WITH PROGRESSIVE DISEASE FOLLOWING PRIOR THERAPY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2832342	⤷ Start Trial
Cyprus	1123010	⤷ Start Trial
Denmark	2701708	⤷ Start Trial
Denmark	3679934	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: RE46290